QIAGEN N.V.
Company Information
Industry
Biological Products, (No Diagnostic Substances)
SIC Code
2836
Entity Type
other
SEC Category
Large accelerated filer
State of Incorporation
Netherlands
Country
Netherlands
Business Address
HULSTERWEG 82, PL VENLO, , 5912 PL
Mailing Address
HULSTERWEG 82, PL VENLO, , 5912 PL
Phone
31-77-35566-00
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$3.81B
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 20-F Foreign company annual report | March 20, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 10, 2026 | View on SEC |
| 6-K Foreign company current report | February 6, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 6, 2026 | View on SEC |
| 6-K Foreign company current report | December 22, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 12, 2025 | View on SEC |
| 6-K Foreign company current report | November 6, 2025 | View on SEC |
| 6-K Foreign company current report | November 6, 2025 | View on SEC |
| 6-K Foreign company current report | September 2, 2025 | View on SEC |
| 6-K Foreign company current report | August 21, 2025 | View on SEC |
Annual Reports
20-F
March 20, 2026
- Reported $2.15 billion in total sales for 2025, a 3.5% increase from 2024, driven by non-COVID products.
- Adjusted profit per share increased by 7.7% to $2.10 in 2025, with profit for shareholders rising 7.8% to $485 million.
Related Companies
Companies in the same industry (SIC: 2836)
NEUROCRINE BIOSCIENCES INC
NBIX
Biological Products, (No Diagnostic Substances)
Vor Biopharma Inc.
VOR
Biological Products, (No Diagnostic Substances)
Replimune Group, Inc.
REPL
Biological Products, (No Diagnostic Substances)
BioAtla, Inc.
BCAB
Biological Products, (No Diagnostic Substances)
Vericel Corp
VCEL
Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.